Current oncology最新文献

{"title":"MET Exon 14 Skipping Mutations in Lung Cancer: Clinical-Pathological Characteristics and Immune Microenvironment.","authors":"Qianqian Xue, Yue Wang, Qiang Zheng, Ziling Huang, Yicong Lin, Yan Jin, Yuan Li","doi":"10.3390/curroncol32070403","DOIUrl":"10.3390/curroncol32070403","url":null,"abstract":"<p><p>MET exon 14 skipping mutations have emerged as significant driver alterations in non-small-cell lung cancer (NSCLC), contributing to tumor progression. This study examines the immune microenvironment in NSCLC patients with these mutations and its prognostic implications. We performed multiplex immunofluorescence (mIF) staining on formalin-fixed paraffin-embedded (FFPE) tissue samples from nine NSCLC patients, including four recurrent/metastatic and five non-recurrent/non-metastatic patients. Two panels assessed immune cell markers (CD8, CD4, CD20, CD68, and FoxP3) and immune checkpoints (PD-L1, LAG3, and TIM3). Immune cell infiltration and checkpoint expression were analyzed using HALO^TM software (version 3.6.4134.464). Nearest neighbor analysis was conducted to assess the proximity of immune cells to tumor cells. Univariate Cox regression analysis assessed factors associated with disease-free survival (DFS). CD8+TIM3+ and CD8+LAG3+ cells were predominantly located in the tumor parenchyma of recurrent/metastatic patients but localized to the stroma in non-recurrent/non-metastatic patients. Non-recurrent/non-metastatic patients exhibited a higher density of tertiary lymphoid structures and closer proximity of CD20+ B cells, CD8+TIM3+, and CD8+LAG3+ cells to tumor cells compared to recurrent/metastatic patients, though the differences were not statistically significant. Cox regression analysis suggested a potential association between higher densities of CD8+TIM3+ cells and improved DFS (HR = 0.89), though these findings did not reach statistical significance. Our findings suggest that differences in immune microenvironmental factors, particularly those related to immune checkpoint expression (TIM3 and LAG3), may influence clinical outcomes in NSCLC patients with MET exon 14 skipping mutations. Further studies are needed to validate these observations and explore potential therapeutic implications.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 7","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12293242/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing Adjuvant Care in Early Breast Cancer: Multidisciplinary Strategies and Innovative Models from Canadian Centers.","authors":"Angela Chan, Nancy Nixon, Muna Al-Khaifi, Alain Bestavros, Christine Blyth, Winson Y Cheung, Caroline Hamm, Thomas Joly-Mischlich, Mita Manna, Tom McFarlane, Laura V Minard, Sarah Naujokaitis, Christine Peragine, Cindy Railton, Scott Edwards","doi":"10.3390/curroncol32070402","DOIUrl":"10.3390/curroncol32070402","url":null,"abstract":"<p><p>The adjuvant treatment landscape for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC) is rapidly evolving, with a diverse range of therapeutic options-including endocrine therapies, bisphosphonates, ovarian function suppression, olaparib, CDK4/6 inhibitors, and emerging agents such as immunotherapy. While these advances have markedly improved patient outcomes, they also introduce challenges related to implementation, monitoring, and resource allocation. Notably, therapies like CDK4/6 inhibitors require particularly close monitoring, creating logistical and capacity challenges for medical oncologists, whose workloads are already stretched due to rising cancer incidence and treatment complexities. These challenges underscore the need for innovative care delivery solutions to ensure patients with EBC continue to receive optimal care. This paper offers a comprehensive guide-a playbook-of multidisciplinary-team-based care models designed to optimize adjuvant treatment delivery in EBC. Drawing on real-world evidence and successful applications across Canadian centers, we explore models led by nurses, nurse practitioners (NPs), general practitioners in oncology (GPO), and pharmacists. Each model leverages the unique expertise of its team to manage treatment toxicities, facilitate adherence, and enhance patient education, thereby promoting effective and sustainable care delivery. Importantly, these models are not intended to compete with one another, but rather to serve as a flexible recipe book from which breast cancer care teams can draw strategies tailored to their local resources and patient needs. By detailing implementation strategies, benefits, and challenges-in many instances supported by quantitative metrics and economic evaluations-this work aims to inspire care teams nationwide to optimize the adjuvant management of patients with HR+, HER2- EBC.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 7","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12293295/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential BACH1 Expression in Basal-like Breast Tumors of Black Women Identified via Immunohistochemistry.","authors":"N M Dowling, Galina Khramtsova, Olufunmilayo Olopade, Shabnam Samankan, Bok-Soon Lee, Jiyoung Lee","doi":"10.3390/curroncol32070404","DOIUrl":"10.3390/curroncol32070404","url":null,"abstract":"<p><p>BACH1 has been identified as a functional regulator of cancer metastasis and metabolic signaling in breast cancer cells. However, the clinical relevance of BACH1 expression in breast tumors remains poorly understood. Using a tissue microarray from a cohort of 130 patients, we assessed the expression of BACH1 and its known target gene, MCT1 (encoded by <i>SLC16A1</i>), through immunohistochemistry (IHC). The expression data were then analyzed in relation to clinical variables, including breast cancer subtypes, tissue types, tumor size and grade, patient racial background, and age group. We found positive associations between BACH1 expression and tumor size, tumor grade, and the basal-like subtype. Importantly, BACH1 expression was significantly higher in tumors from Black women compared to those from White women, as well as in the basal-like subtype of breast tumors from Black women. Additionally, a positive correlation was observed between BACH1 and MCT1 IHC scores in tumors from Black women, while a weak association was noted in tumors from White women. Our study provides compelling evidence that BACH1 expression is evident based on the race and subtypes of breast cancer patients.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 7","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12293708/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Matched Case-Control Study Examining the Association Between Exposure to Depot Medroxyprogesterone Acetate and Cerebral Meningioma Using an Active Comparator.","authors":"Russell Griffin, Rebecca Arend","doi":"10.3390/curroncol32070401","DOIUrl":"10.3390/curroncol32070401","url":null,"abstract":"<p><p>The recent literature has reported an increased association between the use of depot medroxyprogesterone acetate (dMPA) and cerebral meningioma (CM). Prior studies have been limited in generalizability and did not use an active comparator as a control. The current matched case-control study utilized a bootstrapped sampling design, matching 241 CM cases with controls (i.e., women diagnosed with non-meningioma brain, breast, or skin tumor, one control per type for three total) on age ± 5 years and diagnosis date ± 3 months. Conditional logistic regression was used to estimate odds ratios (ORs) compared with an active (norethindrone or levonorgestrel) and non-active control group. Exposure to dMPA at any time point was not associated with the diagnosis of cerebral meningioma (OR 1.75, 95% CI 0.81-4.95). Exposure to dMPA within a year of diagnosis was associated with the diagnosis of CM compared to both an active control (OR 3.38, 95% CI 1.13-9.70) and a non-active control (OR 6.90, 95% CI 2.31-17.58). This association was also present for those who were exposed within two years prior when compared to a non-active control (OR 3.54, 95% CI 1.50-11.88) but not an active control. Combined with the prior literature, the current results suggest that future research is warranted to understand this association.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 7","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12293745/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Gratitude Journaling on Patients with Breast Cancer: A Randomized Controlled Trial.","authors":"Minjeong You, Eunjung Kim","doi":"10.3390/curroncol32070400","DOIUrl":"10.3390/curroncol32070400","url":null,"abstract":"<p><p>Gratitude journaling is a simple and effective way to improve emotional well-being. However, its impact on people with breast cancer in South Korea has not been clearly understood. This study explored how writing a gratitude journal can help patients with breast cancer feel more grateful, resilient, and satisfied with life. Sixty patients from a university hospital in Jeollanam-do were randomly assigned to either a gratitude journaling group or a control group. The journaling group received guidance and wrote at least ten journal entries over three weeks, with weekly phone check-ins. The control group received no intervention. Before and after the program, the participants completed surveys. The results showed that those who kept gratitude journals had higher levels of gratitude, resilience, and quality of life than those who did not. These findings suggest that gratitude journaling can be a valuable and easy-to-use nursing strategy to support the emotional health of breast cancer patients.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 7","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12293474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Continuity of Cancer Care: Female Participants' Report of Healthcare Experiences After Conclusion of Primary Treatment.","authors":"Mirna Becevic, Garren Powell, Allison B Anbari, Jane A McElroy","doi":"10.3390/curroncol32070399","DOIUrl":"10.3390/curroncol32070399","url":null,"abstract":"<p><strong>Background: </strong>Understanding patient perceptions of cancer care is crucial for improving treatment experiences and health outcomes. This study explores female patient-reported experiences with cancer care. Our aim was to identify areas for improvement and enhance patient-centered approaches in specialty and primary care settings.</p><p><strong>Methods: </strong>This was a prospective observational study using ResearchMatch. Our eligibility criteria were 40 years or older adult cancer diagnosis, female, and treated for cancer in the United States.</p><p><strong>Results: </strong>Among the eligible participants (<i>n</i> = 1224), 64 responded to the invitation and 57 completed the survey (89% participation proportion). The majority of the respondents were not receiving treatment during the study period (68%). Of those, 89% completed the recommended treatment, and 10% stopped the treatment before completion. Nearly 80% of respondents saw the same oncologist during the treatment at every appointment, and only 8% reported changing clinicians during their primary cancer treatment. Over 63% of respondents were not seeing the same primary care clinician as they did when they were first diagnosed. Respondents reported facing challenges with employment and ability to return to work (26%), being able to afford medication (21%), and paying medical bills (15%).</p><p><strong>Discussion: </strong>This study, albeit for a small number of participants (<i>n</i> = 57) identified strengths and challenges in cancer care. Consistent oncologist involvement and proximity to care centers was consistently reported during active treatment. Discontinuity with primary care, however, may warrant further inquiry. Reported financial, employment and access issues support previous studies that identified these as major challenges during and after active cancer treatment. Our study underscored the need to enhance patient-centered coordination and support to improve cancer and survivorship care outcomes.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 7","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12294017/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Outcomes in Patients with Squamous Cell Carcinoma of the Urinary Bladder: A Propensity Score-Matched Analysis.","authors":"Alper Coskun, Ahmet Bilgehan Sahin, Selva Kabul, Muhammed Abdurrahman Celik, Mursel Sali, Ender Eren Ozcelik, Adem Deligonul, Erdem Cubukcu, Meral Kurt, Gursel Savci, Turkkan Evrensel, Ismet Yavascaoğlu","doi":"10.3390/curroncol32070394","DOIUrl":"10.3390/curroncol32070394","url":null,"abstract":"<p><strong>Background and objective: </strong>Bladder cancer (BC) is the ninth most common malignancy worldwide. Squamous cell carcinoma (SqCC), a rare histological variant, accounts for approximately 2-5% of all BC cases. Compared to urothelial carcinoma, the predominant subtype, research on SqCC remains limited and shows inconsistent findings regarding prognosis. This study aimed to compare survival outcomes between patients with SqCC and those with pure urothelial carcinoma (PUC).</p><p><strong>Methods: </strong>This retrospective, observational study analyzed pathology reports from 2549 transurethral resections of bladder tumors and 632 cystectomies performed at our institution between 1 December 2010 and 31 December 2023. Following pathological re-evaluation, 33 patients with SqCC and 132 with PUC were identified. After 1:3 propensity score matching, 20 patients with SqCC and 58 with PUC were included in the final analysis. Demographic, clinicopathological features, and survival outcomes were compared between groups.</p><p><strong>Results: </strong>The median follow-up was 2.31 years (range: 0.17-13.50). No significant differences in baseline demographic or clinical characteristics were observed, except for the type of surgery. Kaplan-Meier analysis demonstrated no significant differences in disease-free survival (DFS; <i>p</i> = 0.961) or overall survival (OS; <i>p</i> = 0.847) between SqCC and PUC groups. Multivariate Cox regression analysis identified T stage, nodal involvement, and adjuvant chemotherapy (CT) as independent predictors of DFS, while sex and metastasis at diagnosis were significant predictors of OS.</p><p><strong>Conclusion: </strong>Survival outcomes (DFS and OS) did not significantly differ between patients with SqCC and patients with PUC. Prognosis was more closely associated with disease stage at diagnosis, sex, and adjuvant CT. Further large-scale studies are warranted.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 7","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12293893/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perioperative Chemo/Immunotherapies in Lung Cancer: A Critical Review on the Value of Perioperative Sequences.","authors":"Thoma' Dario Clementi, Francesca Colonese, Stefania Canova, Maria Ida Abbate, Luca Sala, Francesco Petrella, Gabriele Giuseppe Pagliari, Diego Luigi Cortinovis","doi":"10.3390/curroncol32070397","DOIUrl":"10.3390/curroncol32070397","url":null,"abstract":"<p><p>Resectable non-small cell lung cancer (NSCLC) continues to pose significant challenges with high recurrence and mortality rates, despite traditional platinum-based chemotherapy yielding only an approximate 5% improvement in 5-year overall survival when administered preoperatively or postoperatively. In recent years, the integration of immune checkpoint inhibitors (ICIs), such as nivolumab, durvalumab and pembrolizumab, with platinum-based regimens in the perioperative setting has emerged as a transformative strategy. Our comprehensive review, based on a systematic bibliographic search of PubMed, Google Scholar, EMBASE, Cochrane Library, and clinicaltrials.gov, targeting pivotal clinical trials from the past two decades, examines the impact of these neoadjuvant and adjuvant chemoimmunotherapy approaches on major pathological response rates and overall survival in early-stage NSCLC. Although these perioperative strategies represent a paradigm shift in treatment, promising durable responses are offset by persistent recurrence, emphasizing the necessity for optimized treatment sequencing, duration, and the identification of predictive biomarkers. Collectively, our findings underscore the critical role of the perioperative schema, particularly the neoadjuvant component, which enables the evaluation of novel biomarkers as surrogates for overall survival, in improving patient outcomes and delineating future research directions aimed at reducing mortality and enhancing the quality of life for patients with resectable NSCLC.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 7","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12293282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prioritizing the Timely Detection and Diagnosis of Early-Age Onset Cancer to Enable Optimal Disease Management and Outcomes.","authors":"Michael J Raphael, Petra Wildgoose, Darren Brenner, Christine Brezden-Masley, Ronald Burkes, Robert C Grant, Alexandra Pettit, Cassandra Macaulay, Monika Slovinec D'Angelo, Filomena Servidio-Italiano","doi":"10.3390/curroncol32070396","DOIUrl":"10.3390/curroncol32070396","url":null,"abstract":"<p><p>In November 2024, the fourth annual Symposium focusing on early-age onset cancer (EAOC) was hosted by the Colorectal Cancer Resource & Action Network (CCRAN), assembling clinicians, researchers, and patients virtually to discuss challenges in early detection and diagnosis of individuals afflicted with EAOC across tumour types. The meeting addressed the rising rates of EAOC and identified strategies to overcome barriers to timely detection and diagnosis by closing gaps in public and healthcare provider knowledge on symptoms of cancer in younger adults and reducing inequities in standard screening for younger age groups. Discussions also encompassed the various factors that serve as impediments to accessing diagnostic testing and obtaining results, as well as the critical need for access to diagnostics such as comprehensive genomic profiling (CGP), the results of which could be imperative in helping to guide clinical decisions regarding effective and well-tolerated targeted therapies. The Symposium generated key calls to action regarding increasing EAOC education and awareness among primary care providers and the public, re-evaluation of cancer screening programs' eligibility criteria to include younger populations, and mechanisms to reduce waiting times for diagnostic testing by addressing technologist shortages and improving access to CGP through national collaborative strategies and increased funding.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 7","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12293352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pre-Implementation Assessment of a Sexual Health eClinic in Canadian Oncology Care.","authors":"Taylor Incze, Dalia Peres, Steven Guirguis, Sarah E Neil-Sztramko, Jackie Bender, Dean Elterman, Shabbir M H Alibhai, Antonio Finelli, Phil Vu Bach, Emily Belita, Gerald Brock, Julia Brown, Jeffrey Campbell, Trustin Domes, Andrew Feifer, Ryan Flannigan, Celestia Higano, Jesse Ory, Premal Patel, Monita Sundar, Luke Witherspoon, Andrew Matthew","doi":"10.3390/curroncol32070395","DOIUrl":"10.3390/curroncol32070395","url":null,"abstract":"<p><p>Sexual dysfunction is a prevalent and often under-addressed concern among prostate cancer survivors, significantly affecting quality of life for patients and their partners. The True North Sexual Health and Rehabilitation eClinic (SHAReClinic) is a virtual, biopsychosocial intervention developed to improve access to sexual health support for prostate cancer survivors and their partners. This study used a qualitative descriptive design to examine barriers and facilitators influencing the integration of SHAReClinic into oncology care across nine Canadian health care centres. Semi-structured interviews were conducted with 17 knowledge users, including health care providers and institutional leaders. Data were analyzed using a hybrid deductive-inductive thematic approach guided by the Consolidated Framework for Implementation Research (CFIR) 2.0. Participants described SHAReClinic as a much-needed resource, particularly in the absence of standardized sexual health pathways in oncology care. The virtual format was seen as accessible and well suited to addressing sensitive topics. However, limited funding, lack of institutional support, and workflow integration challenges emerged as primary barriers to implementation. Findings offer practical, theory-informed guidance for integrating SHAReClinic into oncology care and highlight key considerations for developing sustainable and scalable survivorship care models.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 7","pages":""},"PeriodicalIF":3.4,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12293689/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}